Elevian
Menlo Park, US · Founded 2017 · Delaware corporation · 5 employees on LinkedIn · 7 known investors
Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.
Founders & leadership
Elevian was founded in 2017 by Mark Allen.
MA
Mark AllenFounder
CJ
Casey J McGlynnNamed on SEC filing
SG
Sebastian GiwaNamed on SEC filing
LA
Luis AlvarezNamed on SEC filing
DM
Daniel MarshakNamed on SEC filing
Board
SF
Suzanne FletcherBoard director
Investors · 7
Reported raises · per SEC filings
Form D private placements$38M disclosed across 2 rounds · 2020–2021
▶$22.7MraisedSep 2021 · 29 investors · OtherRule 506(b)
▶$22.7MraisedSep 2021 · 29 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- J. Casey McGlynnExecutive Officer
- Mark AllenExecutive Officer, Director
- Daniel MarshakDirector
- Brandon SimmonsDirector
- Caleb BellDirector
- Sebastian GiwaExecutive Officer, Director
- Offering amount
- $42.7M
- Amount sold
- $22.7M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$15.3MraisedJul 2020 · 68 investors · OtherRule 506(b)
▶$15.3MraisedJul 2020 · 68 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Suzanne FletcherDirector
- Casey J McGlynnExecutive Officer
- Mark AllenExecutive Officer, Director
- Sebastian GiwaExecutive Officer, Director
- Luis AlvarezExecutive Officer
- Daniel MarshakDirector
- Offering amount
- $15.4M
- Amount sold
- $15.3M
- Minimum investment
- $1
- First sale
- Jul 2020
- Incorporated
- Corporation, California, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
IQVIA27 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Bioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Elevian for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Elevian do?
- Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.
- Who founded Elevian?
- Elevian was founded by Mark Allen in 2017.
- Who are Elevian's investors?
- Elevian's investors include Bold Capital Partners, Thynk Capital, BOLD Capital, For Good Ventures, Lauder Partners, Prime Movers Lab, WTI.
- How much funding has Elevian raised?
- Elevian has disclosed $38M raised across 2 rounds.
- Where is Elevian headquartered?
- Elevian is headquartered in Menlo Park, US.